Tirzepatide
Often called a "twincretin," this dual-action peptide is currently the most potent FDA-approved weight-loss tool.
What it is
Tirzepatide is a first-of-its-kind "dual agonist." While Semaglutide targets one hormone (GLP-1), Tirzepatide targets two: GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide). It was developed by Eli Lilly and is sold under the brand names Mounjaro (for diabetes) and Zepbound (for weight loss).
We often describe Tirzepatide as a "next-generation" metabolic peptide. By combining two different hormonal pathways, it aims to achieve better blood sugar control and weight loss with potentially fewer gastrointestinal side effects than GLP-1-only medications.
What it does
By activating both the GIP and GLP-1 receptors, Tirzepatide works on multiple levels. The GIP component is thought to improve how the body breaks down fat and sugar while also acting on the brain to reduce nausea. The GLP-1 component, like Semaglutide, slows digestion and suppresses appetite.
The result is a powerful metabolic reset. Users pursue it for profound weight loss and the resolution of metabolic syndrome. Research also suggests it may have positive effects on liver fat and kidney function, making it a comprehensive tool for metabolic health.
What the evidence says
The evidence for Tirzepatide is landmark-level. In the SURMOUNT-1 clinical trial, participants on the highest dose lost an average of 20.9% of their body weight—results previously seen only with bariatric surgery. It consistently outperforms Semaglutide in head-to-head trials for both weight loss and A1C reduction.
While the data is robust, researchers are still investigating the long-term effects of dual-hormone agonism. The safety profile appears very similar to Semaglutide, but because it is newer (approved in 2022), we have slightly less long-term real-world data than we do for older GLP-1s.
What it costs
Tirzepatide is currently one of the most expensive peptides on the market. Without insurance, the retail price for Zepbound or Mounjaro is roughly $1,050 to $1,200 per month. While some savings cards are available from the manufacturer, the high demand has also led to frequent supply shortages.
Side effects and risks
Nausea, diarrhea, and decreased appetite are the most common reports. Because it is so potent, some users experience "sulfur burps" or significant fatigue during the first few weeks. Serious risks are similar to other incretins: pancreatitis, gallbladder disease, and kidney issues related to dehydration.
The FDA's enforcement discretion for compounded tirzepatide ended in early 2025; warning letters and lawsuits against compounded copies have intensified through 2026.
Where users source it
This is a prescription medication. We cannot overstate the importance of getting Tirzepatide from a licensed pharmacy. Due to its popularity, counterfeit versions have been found in the "gray market," often containing incorrect dosages or harmful contaminants.
Sources
- Jastreboff AM, et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. PMID 35658024
- Rosenstock J, et al. (2021). "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." NEJM. PMID 34170647
- Fierce Pharma. (March 2026). "FDA ramps up crackdown on GLP-1 drug compounders with fresh batch of 30 warning letters."
- FDA. (2022). "FDA Approves Novel Dual-Targeted Treatment for Type 2 Diabetes."
A breakthrough GLP-1 medication that has transformed how we approach weight management and metabolic health.
The "Triple G" peptide currently in final testing, promising even greater weight loss than its predecessors.
Often called the "Body Protection Compound," this gastric-derived peptide is a staple in recovery research circles.